E EXELIXIS INC.
| Market Cap | $11.76B |
| P/E Ratio | 15.78 |
| Forward P/E | 11.17 |
| Dividend Yield | — |
| Beta | 0.42 |
| 52W Range | $34.13 - $46.61 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 0.00% | $550.00K | 12,571 | Reduce 22.74% |
Insider Trading
| Insider Name of the company insider who made the trade 28 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Aftab DanaEVP, Research and Development | Sale | 47,918 | $44.50 | $2.13M | 24 Feb 2026 | 26 Feb 2026 |
| Aftab DanaEVP, Research and Development | Sale | 29,873 | $44.35 | $1.32M | 19 Feb 2026 | 23 Feb 2026 |
| Smith Julie | Sale | 20,030 | $44.30 | $887.33K | 18 Feb 2026 | 19 Feb 2026 |
| Smith Julie | Sale | 44,087 | $44.50 | $1.96M | 18 Feb 2026 | 19 Feb 2026 |
| WYSZOMIERSKI JACK L | Sale | 99,574 | $44.01 | $4.38M | 18 Feb 2026 | 20 Feb 2026 |
| Hefti BrendaSVP and General Counsel | Sale | 18,669 | $44.01 | $821.62K | 18 Feb 2026 | 18 Feb 2026 |
| Senner Christopher J.EVP and CFO | Sale | 30,617 | $43.67 | $1.34M | 17 Feb 2026 | 18 Feb 2026 |
| Haley Patrick J.EVP, Commercial | Sale | 64,778 | $43.50 | $2.82M | 17 Feb 2026 | 18 Feb 2026 |
| Haley Patrick J.EVP, Commercial | Sale | 3,036 | $43.84 | $133.10K | 17 Feb 2026 | 18 Feb 2026 |
| Smith Julie | Sale | 42,422 | $43.33 | $1.84M | 17 Feb 2026 | 19 Feb 2026 |
| Eckhardt Sue Gail | Sale | 3,856 | $43.79 | $168.85K | 13 Feb 2026 | 18 Feb 2026 |
| Oliver Bob | Sale | 21,162 | $43.90 | $929.01K | 13 Feb 2026 | 18 Feb 2026 |
| Oliver Bob | Sale | 9,088 | $43.61 | $396.33K | 13 Feb 2026 | 18 Feb 2026 |
| Senner Christopher J.EVP and CFO | Sale | 34,278 | $43.00 | $1.47M | 13 Feb 2026 | 18 Feb 2026 |
| JOHNSON DAVID EDWARD | Buy | 27,532 | $43.12 | $1.19M | 25 Nov 2025 | 26 Nov 2025 |
| David Edward JohnsonDirector/ Director | Buy | 27,532 | $43.12 | $1.19M | 25 Nov 2025 | 26 Nov 2025 |
| Haley Patrick J.EVP, Commercial | Sale | 28,043 | $42.58 | $1.19M | 21 Nov 2025 | 24 Nov 2025 |
| Patrick J. HaleyEVP, Commercial | Sale | 28,043 | $42.58 | $1.19M | 21 Nov 2025 | 24 Nov 2025 |
| Haley Patrick J.EVP, Commercial | Sale | 10,000 | $42.11 | $421.10K | 20 Nov 2025 | 24 Nov 2025 |
| Haley Patrick J.EVP, Commercial | Sale | 10,648 | $41.77 | $444.77K | 20 Nov 2025 | 24 Nov 2025 |
| Haley Patrick J.EVP, Commercial | Sale | 23,539 | $41.93 | $986.99K | 20 Nov 2025 | 24 Nov 2025 |
| Patrick J. HaleyEVP, Commercial | Sale | 23,539 | $41.93 | $986.99K | 20 Nov 2025 | 24 Nov 2025 |
| Patrick J. HaleyEVP, Commercial | Sale | 10,648 | $41.77 | $444.77K | 20 Nov 2025 | 24 Nov 2025 |
| Patrick J. HaleyEVP, Commercial | Sale | 10,000 | $42.11 | $421.10K | 20 Nov 2025 | 24 Nov 2025 |
| PAPADOPOULOS STELIOS | Sale | 100,000 | $43.55 | $4.36M | 12 Nov 2025 | 13 Nov 2025 |
| Aftab DanaEVP, Research and Development | Sale | 48,383 | $42.50 | $2.06M | 11 Nov 2025 | 13 Nov 2025 |
| Beckerle Mary C | Sale | 5,784 | $42.03 | $243.10K | 11 Nov 2025 | 13 Nov 2025 |
| Beckerle Mary C | Sale | 18,838 | $41.90 | $789.31K | 11 Nov 2025 | 13 Nov 2025 |
Frequently Asked Questions
What is EXEL stock price today?
EXELIXIS INC. (EXEL) is currently trading at $43.88. The stock has a 52-week range of $34.13 to $46.61 and a market capitalization of $11.76B.
Is EXEL a good stock to buy in 2026?
EXELIXIS INC. has a P/E ratio of 15.8 (forward P/E: 11.2), a dividend yield of none, and 1-year performance of +19.6%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling EXEL stock?
There have been 28 insider transactions for EXEL in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has EXEL stock performed over the past year?
EXELIXIS INC. (EXEL) has returned +19.6% over the past 12 months. The stock traded between $34.13 and $46.61 during this period, and is currently at $43.88.
Which hedge funds own EXEL (EXELIXIS INC.)?
1 tracked hedge funds currently hold EXEL in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is EXEL's market cap and valuation?
EXELIXIS INC. (EXEL) has a market capitalization of $11.76B. The trailing P/E ratio is 15.8 and forward P/E is 11.2. The stock is classified in the Healthcare sector.
What is EXEL's revenue and profitability?
EXELIXIS INC. reported revenue of $2.32B with net income of $782.57M and a profit margin of 0.34%. The stock has a beta of 0.42.
What sector is EXEL in and who are its biggest institutional holders?
EXELIXIS INC. (EXEL) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.